Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients

被引:11
|
作者
Lloyd-Jones, Donald M.
Huffman, Mark D.
Karmali, Kunal N.
Sanghavi, Darshak M.
Wright, Janet S.
Pelser, Colleen
Gulati, Martha
Masoudi, Frederick A.
Goff, David C., Jr.
机构
关键词
AHA Scientific Statements; cardiovascular diseases; morbidity; mortality; myocardial infarction; population; prevention; stroke; ASSOCIATION TASK-FORCE; ADULT TREATMENT PANEL; OUTCOME INCIDENCE; NATIONAL-HEALTH; MULTIFACTORIAL INTERVENTION; MYOCARDIAL-INFARCTION; STATIN ELIGIBILITY; LOWERING TREATMENT; AMERICAN-COLLEGE; UNITED-STATES;
D O I
10.1016/j.jacc.2016.10.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk"by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.
引用
收藏
页码:1617 / 1636
页数:20
相关论文
共 50 条
  • [41] Cost-related medication nonadherence among Medicare beneficiaries with cardiovascular disease risk factors: The role of comprehension of the Medicare programme and its prescription drug benefits
    Park, Chanhyun
    Chang, Chiu-chi Angela
    Ng, Boon Peng
    Young, Gary J.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2023, 29 (01) : 136 - 145
  • [42] Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
    Li, Daniel
    Feldman, Candace
    Guan, Hongshu
    Everett, Brendan
    Kim, Seoyoung C.
    Costenbader, Karen
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer
    Petrillo, Laura A.
    Zhou, Ashley Z.
    Sullivan, Ryan
    Volandes, Angelo
    Greer, Joseph A.
    Temel, Jennifer S.
    El-Jawahri, Areej
    ONCOLOGIST, 2021, 26 (11): : E2090 - E2093
  • [44] Perceptions of the Benefits and Risks of Antibiotics Among Adult Patients and Parents With High Antibiotic Utilization
    Spicer, Jennifer O.
    Roberts, Rebecca M.
    Hicks, Lauri A.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (12):
  • [45] Interchangeability among therapeutics equivalents of lamotrigine in the treatment of refractory epilepsy patients: risks and benefits
    Girolineto, Beatriz M. P.
    Alexandre, Veriano, Jr.
    Queiroz, Regina H. C.
    Feletti, Fausto
    Sakamoto, Americo C.
    Pereira, Leonardo R. L.
    REVISTA DE NEUROLOGIA, 2010, 51 (06) : 330 - 336
  • [46] Understanding of seasonal influenza immunisation and its cardiovascular benefits among cardiology patients
    Monagle, S. R.
    Spear, E.
    Thakur, U.
    Pol, D.
    Tan, S.
    Bellamy, K.
    Hickman, J.
    Jackson, B.
    Chan, J.
    Nicholls, S. J.
    Nelson, A. J.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [47] Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
    Ridker, Paul M.
    Pradhan, Aruna
    MacFadyen, Jean G.
    Libby, Peter
    Glynn, Robert J.
    LANCET, 2012, 380 (9841): : 565 - 571
  • [48] Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry)
    Daimee, Usama A.
    Aslam, Faisal
    Parzynski, Craig S.
    Desai, Nihar R.
    Curtis, Jeptha P.
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 155 : 64 - 71
  • [49] Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction and estimating benefits from novel interventions
    Welsh, P.
    Welsh, C.
    Celis-Morales, C. A. C.
    Brown, R.
    Ferguson, L. D.
    Gray, S.
    Mark, P.
    Lewsey, J.
    Lyall, D. M.
    Gill, J. M. R.
    Pell, J.
    Jhund, P. S.
    De Lemos, J. A.
    Willeit, P.
    Sattar, N.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2833 - 2833
  • [50] Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions
    Welsh, Paul
    Welsh, Claire
    Celis-Morales, Carlos A.
    Brown, Rosemary
    Ho, Frederick K.
    Ferguson, Lyn D.
    Mark, Patrick B.
    Lewsey, James
    Gray, Stuart R.
    Lyall, Donald M.
    Gill, Jason M. R.
    Pell, Jill P.
    de Lemos, James A.
    Willeit, Peter
    Sattar, Naveed
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 28 (18) : 1991 - 2000